Clinical Trial Update: Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

The document reports the completion of a Phase 2/Phase 3 clinical trial evaluating TG4010 immunotherapy in patients with advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TG4010 (MVA-MUC1-IL-2 therapeutic cancer vaccine)

Snippet

Sponsor: Transgene | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2, Phase 3 | Status: COMPLETED